Author

John Liu 1

1 Abbvie,North Chicago,United States

CLINICALLY ADJUSTED VERSUS THERAPEUTIC DRUG MONITORING DOSING REGIMENS WITH ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE SERENE-CD MAINTENANCE STUDY

Silvio Danese, William Sandborn, Edward V. Loftus Jr., Stephen B Hanauer, Stefan Schreiber, Laurent Peyrin-Biroulet, Remo Panaccione, Julian Panés, Filip Baert, Jean-Frederic Colombel, Marc Ferrante, Edouard Louis, Alessandro Armuzzi, Sasikiran Goteti, John Liu, Nael M. Mostafa, Thao Doan, Joel Petersson, Anne M. Robinson

COMPOSITE AND INDIVIDUAL MEASURES OF EFFICACY AND SAFETY AFTER 2 YEARS OF UPADACITINIB TREATMENT FOR CROHN'S DISEASE: RESULTS FROM THE ONGOING PHASE 2 CELEST OPEN-LABEL EXTENSION STUDY

Geert R. D'Haens, Julian Panés, Edouard Louis, Qian Zhou, John Liu, Ana P. Lacerda, Edward Loftus

Long-term efficacy and safety of upadacitinib treatment in patients with Crohn´s disease: One-year results of the ongoing phase 2 CELEST open-label extension study

Geert R. D'Haens, Julian Panés, Edouard Louis, Qian Zhou, David Pugatch, John Liu, Ana P. Lacerda, Edward Loftus

MATCHING-ADJUSTED INDIRECT COMPARISONOF UPADACITINIB VERSUS VEDOLIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Walter Reinisch, Severine Vermeire, Charlotte Hedin, David T. Rubin, Julian Panés, Huiwen Deng, Si Xuan, Lani Wegrzyn, John Liu, Dapo Ilo, Wen Zhou, Yuri Sanchez Gonzalez, Remo Panaccione

Item 1 - 4 / 4
1